Title:
ANTI-Eva1 PROTEIN ANTIBODY
Document Type and Number:
WIPO Patent Application WO/2017/022668
Kind Code:
A1
Abstract:
The purpose of the present invention is to provide an antibody that produces a high therapeutic and prophylactic effects against cancer and the like. In the present invention, three murine monoclonal antibodies are produced, which demonstrate high affinity for human derived Eva1 protein. A chimeric antibody is also produced, in which constant regions of these antibodies are replaced with human derived regions. Furthermore, these murine antibodies and chimeric antibodies were also found to have high ADCC activity and/or CDC activity. Moreover, it was shown that, by administering these antibodies to mice to which melanoma cells had been administered, metastasis of such cells to the lungs and the like is inhibited.
Inventors:
TAKEMORI TOSHITADA (JP)
SHIROUZU MIKAKO (JP)
TANAKA MIHO (JP)
UESHIMA TAMAMI (JP)
KONDO TORU (JP)
SHIROUZU MIKAKO (JP)
TANAKA MIHO (JP)
UESHIMA TAMAMI (JP)
KONDO TORU (JP)
Application Number:
PCT/JP2016/072348
Publication Date:
February 09, 2017
Filing Date:
July 29, 2016
Export Citation:
Assignee:
RIKEN (JP)
International Classes:
C12N15/09; A61K39/395; A61P35/00; C07K16/30
Domestic Patent References:
| WO2012043747A1 | 2012-04-05 |
Foreign References:
| JP2013203709A | 2013-10-07 |
Other References:
GARABATOS NAHIR ET AL.: "A Monoclonal Antibody Against the Extracellular Domain of Mouse and Human Epithelial V-like Antigen 1 Reveals a Restricted Expression Pattern Among CD 4- CD 8- Thymocytes", MONOCLONAL ANTIBODIES IN IMMUNODIAGNOSIS AND IMMUNOTHERAPY, vol. 33, no. 5, 2014, pages 305 - 311, XP055362425
See also references of EP 3330376A4
See also references of EP 3330376A4
Attorney, Agent or Firm:
CENTCREST IP ATTORNEYS (JP)
Download PDF: